On the public citation graph
Current treatment strategies for advanced prostate cancer
0 signed · 346 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2015.1341openalex-snapshot
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1001/jamaoncol.2016.1828openalex-snapshot
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1002/cncr.28518openalex-snapshot
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment
inferredcites →https://doi.org/10.1002/pros.22674openalex-snapshot
Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancer
inferredcites →https://doi.org/10.1002/pros.23246openalex-snapshot
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration‐Resistant Prostate Cancer: A Retrospective Study
inferredcites →https://doi.org/10.1002/pros.23373openalex-snapshot
Lactate dehydrogenase predicts combined progression‐free survival after sequential therapy with abiraterone and enzalutamide for patients with castration‐resistant prostate cancer
inferredcites →https://doi.org/10.1016/j.cell.2009.04.056openalex-snapshot
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
inferredcites →https://doi.org/10.1016/j.cell.2013.07.029openalex-snapshot
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.cell.2013.11.012openalex-snapshot
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
inferredcites →https://doi.org/10.1016/j.clgc.2014.06.007openalex-snapshot
Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.critrevonc.2015.07.013openalex-snapshot
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
inferredcites →https://doi.org/10.1016/j.ejca.2014.03.010openalex-snapshot
Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
inferredcites →https://doi.org/10.1016/j.ejca.2015.06.128openalex-snapshot
Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer
inferredcites →https://doi.org/10.1016/j.ejca.2015.07.037openalex-snapshot
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
inferredcites →https://doi.org/10.1016/j.ejca.2016.03.070openalex-snapshot
Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors
inferredcites →https://doi.org/10.1016/j.ejca.2017.07.003openalex-snapshot
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.eururo.2013.06.042openalex-snapshot
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
inferredcites →https://doi.org/10.1016/j.eururo.2013.11.044openalex-snapshot
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
inferredcites →https://doi.org/10.1016/j.eururo.2014.01.018openalex-snapshot
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.eururo.2014.04.015openalex-snapshot
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
inferredcites →https://doi.org/10.1016/j.eururo.2014.06.045openalex-snapshot
Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
inferredcites →https://doi.org/10.1016/j.eururo.2014.07.028openalex-snapshot
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
inferredcites →https://doi.org/10.1016/j.eururo.2014.09.022openalex-snapshot
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model
inferredcites →https://doi.org/10.1016/j.eururo.2014.10.014openalex-snapshot
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
inferredcites →https://doi.org/10.1016/j.eururo.2014.10.027openalex-snapshot
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
inferredcites →https://doi.org/10.1016/j.eururo.2014.11.033openalex-snapshot
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.eururo.2015.07.007openalex-snapshot
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
inferredcites →https://doi.org/10.1016/j.eururo.2015.10.021openalex-snapshot
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
inferredcites →https://doi.org/10.1016/j.eururo.2015.11.005openalex-snapshot
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
inferredcites →https://doi.org/10.1016/j.eururo.2015.11.022openalex-snapshot
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.eururo.2016.02.034openalex-snapshot
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.eururo.2016.02.055openalex-snapshot
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.1016/j.eururo.2016.06.033openalex-snapshot
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
inferredcites →https://doi.org/10.1016/j.eururo.2017.06.002openalex-snapshot
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
inferredcites →https://doi.org/10.1016/j.urolonc.2015.12.005openalex-snapshot
First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry
inferredcites →https://doi.org/10.1016/s0140-6736(10)61389-xopenalex-snapshot
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
inferredcites →https://doi.org/10.1016/s0140-6736(15)01037-5openalex-snapshot
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
inferredcites →https://doi.org/10.1016/s0960-0760(96)00225-7openalex-snapshot
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
inferredcites →https://doi.org/10.1016/s1470-2045(09)70229-3openalex-snapshot
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
inferredcites →https://doi.org/10.1016/s1470-2045(12)70560-0openalex-snapshot
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70018-xopenalex-snapshot
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
inferredcites →https://doi.org/10.1016/s1470-2045(14)71205-7openalex-snapshot
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
inferredcites →https://doi.org/10.1021/jm00013a022openalex-snapshot
Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
inferredcites →https://doi.org/10.1038/bjc.2015.332openalex-snapshot
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
inferredcites →https://doi.org/10.1038/bjc.2015.361openalex-snapshot
Serum lactate dehydrogenase and survival following cancer diagnosis
inferredcites →https://doi.org/10.1038/ncomms6548openalex-snapshot
ERG induces taxane resistance in castration-resistant prostate cancer
inferredcites →https://doi.org/10.1038/ng.3419openalex-snapshot
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
inferredcites →https://doi.org/10.1038/nm.4045openalex-snapshot
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6604453openalex-snapshot
Rapid progression of prostate cancer in men with a BRCA2 mutation
inferredcites →https://doi.org/10.1056/nejmoa040720openalex-snapshot
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa041318openalex-snapshot
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1001294openalex-snapshot
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1014618openalex-snapshot
Abiraterone and Increased Survival in Metastatic Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1207506openalex-snapshot
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
inferredcites →https://doi.org/10.1056/nejmoa1209096openalex-snapshot
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
inferredcites →https://doi.org/10.1056/nejmoa1213755openalex-snapshot
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1315815openalex-snapshot
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1405095openalex-snapshot
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
inferredcites →https://doi.org/10.1056/nejmoa1503747openalex-snapshot
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1506859openalex-snapshot
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
inferredcites →https://doi.org/10.1056/nejmoa1702900openalex-snapshot
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
inferredcites →https://doi.org/10.1056/nejmoa1704174openalex-snapshot
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
inferredcites →https://doi.org/10.1073/pnas.1600420113openalex-snapshot
Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression
inferredcites →https://doi.org/10.1074/jbc.a117.553818openalex-snapshot
Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
inferredcites →https://doi.org/10.1074/jbc.m114.553818openalex-snapshot
Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
inferredcites →https://doi.org/10.1074/jbc.m116.718536openalex-snapshot
Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells
inferredcites →https://doi.org/10.1093/annonc/mdt136openalex-snapshot
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
inferredcites →https://doi.org/10.1093/annonc/mdt138openalex-snapshot
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
inferredcites →https://doi.org/10.1093/annonc/mdt581openalex-snapshot
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
inferredcites →https://doi.org/10.1093/annonc/mdu569openalex-snapshot
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
inferredcites →https://doi.org/10.1093/annonc/mdu587openalex-snapshot
Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
inferredcites →https://doi.org/10.1093/annonc/mdv267openalex-snapshot
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
inferredcites →https://doi.org/10.1093/annonc/mdv282openalex-snapshot
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
inferredcites →https://doi.org/10.1093/annonc/mdw372.04openalex-snapshot
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
inferredcites →https://doi.org/10.1093/jjco/hyv070openalex-snapshot
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
inferredcites →https://doi.org/10.1093/jnci/djm005openalex-snapshot
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers
inferredcites →https://doi.org/10.1097/coc.0000000000000181openalex-snapshot
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
inferredcites →https://doi.org/10.1097/pas.0000000000000208openalex-snapshot
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
inferredcites →https://doi.org/10.1111/bju.12867openalex-snapshot
Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer ( mCRPC )
inferredcites →https://doi.org/10.1111/iju.13346openalex-snapshot
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration
inferredcites →https://doi.org/10.1111/j.1464-410x.2005.05821.xopenalex-snapshot
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
inferredcites →https://doi.org/10.1126/science.1117679openalex-snapshot
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
inferredcites →https://doi.org/10.1126/science.aah4199openalex-snapshot
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
inferredcites →https://doi.org/10.1126/science.aah4307openalex-snapshot
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
inferredcites →https://doi.org/10.1126/scitranslmed.aac9511openalex-snapshot
Plasma AR and abiraterone-resistant prostate cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-10-0585openalex-snapshot
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-15-2078openalex-snapshot
Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-2910openalex-snapshot
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2666openalex-snapshot
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-0269openalex-snapshot
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-1070openalex-snapshot
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
inferredcites →https://doi.org/10.1158/2159-8290.cd-11-0130openalex-snapshot
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
inferredcites →https://doi.org/10.1200/jco.2012.30.4_suppl.213openalex-snapshot
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
inferredcites →https://doi.org/10.1200/jco.2012.30.5_suppl.213openalex-snapshot
Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.
inferredcites →https://doi.org/10.1200/jco.2014.32.30_suppl.282openalex-snapshot
Incidence and determinants of 1-month mortality after cancer-directed surgery.
inferredcites →https://doi.org/10.1200/jco.2014.32.31_suppl.188openalex-snapshot
Symptom clustering among patients visiting a supportive oncology clinic.
inferredcites →https://doi.org/10.1200/jco.2014.32.4_suppl.188openalex-snapshot
Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program.
inferredcites →https://doi.org/10.1200/jco.2014.32.4_suppl.282openalex-snapshot
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.5006openalex-snapshot
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).
inferredcites →https://doi.org/10.1200/jco.2016.34.15_suppl.5008openalex-snapshot
Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.5011openalex-snapshot
Whole exome sequencing (WES) of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer (NEPC) informs tumor heterogeneity.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.5012openalex-snapshot
The benefit of combining docetaxel to androgen deprivation therapy in localized and metastatic castration-sensitive prostate cancer as predicted by ERG status: An analysis of two GETUG phase III trials.
inferredcites →https://doi.org/10.1200/jco.2017.35.6_suppl.154openalex-snapshot
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.
inferredcites →https://doi.org/10.1200/jco.2017.35.6_suppl.165openalex-snapshot
Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.
inferredcites →https://doi.org/10.1200/jco.2017.72.4138openalex-snapshot
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.21873/anticanres.11205openalex-snapshot
Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
inferredcites →https://doi.org/10.3109/21681805.2013.860189openalex-snapshot
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
inferredcites →https://doi.org/10.3389/fphar.2016.00123openalex-snapshot
Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5218793openalex-extracted
Research Progress of Imaging Diagnosis and Phototherapy Based on Nanoparticles in Prostate Cancer: A Review
inferred← citeshttps://doi.org/10.1002/1878-0261.13314openalex-snapshot
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
inferred← citeshttps://doi.org/10.1002/1878-0261.13634openalex-snapshot
Acetylated KHSRP impairs DNA ‐damage‐response‐related mRNA decay and facilitates prostate cancer tumorigenesis
inferred← citeshttps://doi.org/10.1002/1878-0261.13641openalex-snapshot
TAS 3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer
inferred← citeshttps://doi.org/10.1002/cam4.70044openalex-snapshot
Epigenome‐wide association study of prostate cancer in African American men identified differentially methylated genes
inferred← citeshttps://doi.org/10.1002/cam4.70226openalex-snapshot
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer
inferred← citeshttps://doi.org/10.1002/cam4.70319openalex-snapshot
Nomogram Analysis for Predicting Response to Androgen‐Receptor‐Axis‐Targeted Therapies in Patients With Metastatic Castration‐Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1002/jbt.22542openalex-snapshot
Cabazitaxel exhibits more favorable molecular changes compared to other taxanes in androgen‐independent prostate cancer cells
inferred← citeshttps://doi.org/10.1002/jbt.23370openalex-snapshot
Silencing LINC00491 inhibits prostate cancer development through the miR‐384/TRIM44 axis
inferred← citeshttps://doi.org/10.1002/mc.23609openalex-snapshot
USF1‐mediated ALKBH5 stabilizes FLII mRNA in an m6A‐YTHDF2‐dependent manner to repress glycolytic activity in prostate adenocarcinoma
inferred← citeshttps://doi.org/10.1002/pros.23661openalex-snapshot
Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide
inferred← citeshttps://doi.org/10.1002/pros.23828openalex-snapshot
Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy
inferred← citeshttps://doi.org/10.1002/pros.24404openalex-snapshot
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1002/pros.24453openalex-snapshot
Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1002/ptr.7614openalex-snapshot
Gambogenic acid induces apoptosis and autophagy through ROS ‐mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells
inferred← citeshttps://doi.org/10.1002/ptr.7631openalex-snapshot
Juglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation
inferred← citeshttps://doi.org/10.1002/tox.23649openalex-snapshot
The toxicity mechanism of glabridin in prostate cancer cells is involved in reactive oxygen species ‐dependent PI3K /Akt pathway: Integrated utilization of bioinformatic analysis and in vitro test validation
inferred← citeshttps://doi.org/10.1007/978-981-95-8644-8_4openalex-snapshot
Electrochemical Biosensor for Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s00109-022-02229-9openalex-snapshot
Functional roles of E3 ubiquitin ligases in prostate cancer
inferred← citeshttps://doi.org/10.1007/s00261-021-03348-6openalex-snapshot
The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists
inferred← citeshttps://doi.org/10.1007/s00280-019-03874-7openalex-snapshot
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study
inferred← citeshttps://doi.org/10.1007/s00289-021-04055-4openalex-snapshot
Two coordination polymers: luminescent, photocatalytic property and enhancement activity on prostate cancer combined with 125I radioactive particle placement
inferred← citeshttps://doi.org/10.1007/s00345-018-2590-2openalex-snapshot
Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan
inferred← citeshttps://doi.org/10.1007/s00345-019-02664-3openalex-snapshot
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s00345-022-04237-3openalex-snapshot
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
inferred← citeshttps://doi.org/10.1007/s00709-021-01608-2openalex-snapshot
Mechanism of WASP and WAVE family proteins in the progression of prostate cancer
inferred← citeshttps://doi.org/10.1007/s10147-024-02649-2openalex-snapshot
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium
inferred← citeshttps://doi.org/10.1007/s10616-026-01056-xopenalex-snapshot
Co-treatment with pyrvinium pamoate and hispidulin potently reduces stemness and promotes mitochondrial apoptosis in prostate cancer cells
inferred← citeshttps://doi.org/10.1007/s10637-018-0685-7openalex-snapshot
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone
inferred← citeshttps://doi.org/10.1007/s10637-023-01330-1openalex-snapshot
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells
inferred← citeshttps://doi.org/10.1007/s10735-026-10825-zopenalex-snapshot
Icariin suppresses glycolysis in prostate cancer by upregulating ALKBH5 to mediate EARS2 m6A demethylation
inferred← citeshttps://doi.org/10.1007/s11010-025-05276-1openalex-snapshot
TOR1 AIP1 interacts with p53 to enhance cell cycle dysregulation in prostate cancer progression
inferred← citeshttps://doi.org/10.1007/s11845-020-02417-xopenalex-snapshot
Post-surgery anxiety and depression in prostate cancer patients: prevalence, longitudinal progression, and their correlations with survival profiles during a 3-year follow-up
inferred← citeshttps://doi.org/10.1007/s11912-024-01614-6openalex-snapshot
Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s12011-023-03668-2openalex-snapshot
Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s12013-023-01156-xopenalex-snapshot
Ubiquitination Process Mediates Prostate Cancer Development and Metastasis through Multiple Mechanisms
inferred← citeshttps://doi.org/10.1007/s12032-019-1257-1openalex-snapshot
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study
inferred← citeshttps://doi.org/10.1007/s12032-019-1332-7openalex-snapshot
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s12094-018-1940-2openalex-snapshot
Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology
inferred← citeshttps://doi.org/10.1007/s12274-023-5541-1openalex-snapshot
Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s12672-025-02265-0openalex-snapshot
Nanotechnology in prostate cancer: a bibliometric analysis from 2004 to 2023
inferred← citeshttps://doi.org/10.1007/s13258-022-01316-yopenalex-snapshot
IDO promotes the proliferation and invasion of prostate cancer cells through KYNU
inferred← citeshttps://doi.org/10.1007/s13577-022-00729-xopenalex-snapshot
ATP-gated P2X7 receptor as a potential target for prostate cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-16032-5.00009-9openalex-snapshot
Novel treatment strategies to overcome resistance in prostate cancer
inferred← citeshttps://doi.org/10.1016/j.bbamcr.2024.119684openalex-snapshot
Raltitrexed induces apoptosis through activating ROS-mediated ER stress by impeding HSPA8 expression in prostate cancer cells
inferred← citeshttps://doi.org/10.1016/j.biocel.2025.106740openalex-snapshot
Ethacrynic acid inhibits the growth and proliferation of prostate cancer cells by targeting GSTP1 and regulating the PI3K-AKT signaling pathway
inferred← citeshttps://doi.org/10.1016/j.cct.2024.107563openalex-snapshot
Applications of wearable activity monitors for prostate cancer survivors: A systematic scoping review
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.115779openalex-snapshot
BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.05.029openalex-snapshot
Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer
inferred← citeshttps://doi.org/10.1016/j.clgc.2019.09.006openalex-snapshot
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study
inferred← citeshttps://doi.org/10.1016/j.clgc.2024.102115openalex-snapshot
A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada
inferred← citeshttps://doi.org/10.1016/j.drup.2022.100865openalex-snapshot
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114506openalex-snapshot
Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study
inferred← citeshttps://doi.org/10.1016/j.ejphar.2024.177149openalex-snapshot
Targets for improving prostate tumor response to radiotherapy
inferred← citeshttps://doi.org/10.1016/j.eurpolymj.2021.110812openalex-snapshot
Overview of chitosan-based nanosystems for prostate cancer therapy
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2020.07.009openalex-snapshot
Mitochondrial functional and structural impairment is involved in the antitumor activity of δ-tocotrienol in prostate cancer cells
inferred← citeshttps://doi.org/10.1016/j.heliyon.2022.e11013openalex-snapshot
3-Deoxysappanchalcone isolated from Caesalpinia sinensis shows anticancer effects on HeLa and PC3 cell lines: invasion, migration, cell cycle arrest, and signaling pathway
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e21174openalex-snapshot
Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing
inferred← citeshttps://doi.org/10.1016/j.ipha.2024.07.001openalex-snapshot
Revolutionizing of bioactive natural products in prostate cancer research and care: Promising discoveries and future directions
inferred← citeshttps://doi.org/10.1016/j.jgo.2020.02.014openalex-snapshot
Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan
inferred← citeshttps://doi.org/10.1016/j.lddd.2025.100047openalex-snapshot
Curcumin-pyrazole a molecular hybrids as potential androgen receptor inhibitors for prostate cancer treatment through molecular docking, ADMET and cytotoxicity prediction, pharmacophore modeling, MDS, and DFT approaches
inferred← citeshttps://doi.org/10.1016/j.matchemphys.2025.131256openalex-snapshot
Integrated experimental and computational insights into thiazolidine derivatives with potent cytotoxicity against PC-3 prostate cancer cells
inferred← citeshttps://doi.org/10.1016/j.ncrna.2024.05.001openalex-snapshot
Exploring the impact of circRNAs on cancer glycolysis: Insights into tumor progression and therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.107932openalex-snapshot
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
inferred← citeshttps://doi.org/10.1016/j.prnil.2022.03.003openalex-snapshot
Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.radonc.2019.08.020openalex-snapshot
Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.08.008openalex-snapshot
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.tox.2022.153178openalex-snapshot
Bisphenol S promotes the progression of prostate cancer by regulating the expression of COL1A1 and COL1A2
inferred← citeshttps://doi.org/10.1016/j.urolonc.2019.04.020openalex-snapshot
Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1016/j.urolonc.2020.09.013openalex-snapshot
Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1021/acsabm.0c01350openalex-snapshot
T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 to Target Androgen-Dependent and Androgen Independent Prostate Cancer
inferred← citeshttps://doi.org/10.1038/s41391-026-01142-3openalex-snapshot
From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer
inferred← citeshttps://doi.org/10.1038/s41397-020-00188-3openalex-snapshot
Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer
inferred← citeshttps://doi.org/10.1038/s41416-023-02448-yopenalex-snapshot
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
inferred← citeshttps://doi.org/10.1038/s41419-023-05694-3openalex-snapshot
Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development
inferred← citeshttps://doi.org/10.1038/s41420-024-01930-7openalex-snapshot
NCAPD3 exerts tumor-promoting effects in prostatic cancer via dual impact on miR-30a-5p by STAT3-MALAT1 and MYC
inferred← citeshttps://doi.org/10.1038/s41467-022-33291-zopenalex-snapshot
Gene expression based inference of cancer drug sensitivity
inferred← citeshttps://doi.org/10.1038/s41585-018-0014-0openalex-snapshot
Personalization of prostate cancer therapy through phosphoproteomics
inferred← citeshttps://doi.org/10.1038/s41598-019-53384-yopenalex-snapshot
Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1038/s41598-021-87441-2openalex-snapshot
Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients
inferred← citeshttps://doi.org/10.1038/s41598-022-06433-yopenalex-snapshot
Detecting disease associated biomarkers by luminescence modulating phages
inferred← citeshttps://doi.org/10.1038/s41598-025-92091-9openalex-snapshot
MiRNA expression profiling and clinical implications in prostate cancer across various stages
inferred← citeshttps://doi.org/10.1038/s41598-026-66577-zopenalex-snapshot
DNA methylation modulation by 5-Azacytidine regulates EMT markers and reduces invasiveness in docetaxel-resistant prostate cancer cells
inferred← citeshttps://doi.org/10.1038/s42003-023-05727-9openalex-snapshot
Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival
inferred← citeshttps://doi.org/10.1038/s42004-025-01744-3openalex-snapshot
A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization
inferred← citeshttps://doi.org/10.1039/d4md00767kopenalex-snapshot
An estrogen receptor β-targeted near-infrared probe for theranostic imaging of prostate cancer
inferred← citeshttps://doi.org/10.1039/d4ra00352gopenalex-snapshot
ROS-responsive polyprodrug micelles carrying suicide genes in combination with chemotherapy and gene therapy for prostate cancer treatment
inferred← citeshttps://doi.org/10.1055/a-1745-8952openalex-snapshot
Prognostic Value of Long Noncoding RNA SNHG11 in Patients with Prostate Cancer
inferred← citeshttps://doi.org/10.1073/pnas.1802354115openalex-snapshot
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
inferred← citeshttps://doi.org/10.1080/0284186x.2023.2175331openalex-snapshot
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
inferred← citeshttps://doi.org/10.1080/03007995.2022.2096353openalex-snapshot
Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan
inferred← citeshttps://doi.org/10.1080/07357907.2020.1871486openalex-snapshot
Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1080/07391102.2023.2213344openalex-snapshot
Investigation on the mechanisms by which the herbal remedies induce anti-prostate cancer activity: uncovering the most practical natural compound
inferred← citeshttps://doi.org/10.1080/1061186x.2021.1892121openalex-snapshot
Nanosystem functionalization strategies for prostate cancer treatment: a review
inferred← citeshttps://doi.org/10.1080/13696998.2022.2066850openalex-snapshot
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada
inferred← citeshttps://doi.org/10.1080/15384101.2021.1992853openalex-snapshot
Exosomal lncAY927529 enhances prostate cancer cell proliferation and invasion through regulating bone microenvironment
inferred← citeshttps://doi.org/10.1080/17435889.2025.2501513openalex-snapshot
From conventional therapy to novel nano-based approaches. A focus on prostate cancer
inferred← citeshttps://doi.org/10.1080/21655979.2022.2037367openalex-snapshot
Circular RNA midline-1 (circMID1) promotes proliferation, migration, invasion and glycolysis in prostate cancer
inferred← citeshttps://doi.org/10.1093/glycob/cwac044openalex-snapshot
Functional analysis of GCNT3 for cell migration and EMT of castration-resistant prostate cancer cells
inferred← citeshttps://doi.org/10.1096/fj.202200673rrropenalex-snapshot
Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor‐promoted inflammatory responses and prostate cancer progression
inferred← citeshttps://doi.org/10.1097/cad.0000000000000884openalex-snapshot
Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study
inferred← citeshttps://doi.org/10.1097/ju.0000000000003370openalex-snapshot
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000016249openalex-snapshot
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
inferred← citeshttps://doi.org/10.1101/2024.10.01.616176openalex-snapshot
CYP3A5 inhibition causes G1/S blockade and synergizes with CDK4/6 inhibitor to suppress prostate cancer cell growth: Implications in reducing health disparity
inferred← citeshttps://doi.org/10.1101/mcs.a006194openalex-snapshot
A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months
inferred← citeshttps://doi.org/10.1111/and.13119openalex-snapshot
Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer
inferred← citeshttps://doi.org/10.1111/and.14227openalex-snapshot
CircRNA pappalysin 1 facilitates prostate cancer development through miR‐515‐5p/FKBP1A axis
inferred← citeshttps://doi.org/10.1111/andr.13219openalex-snapshot
Immunocastration in adult boars as a model for late‐onset hypogonadism
inferred← citeshttps://doi.org/10.1111/bju.15129openalex-snapshot
Not all prostate cancer is the same – patient perceptions: an Asia‐Pacific region study
inferred← citeshttps://doi.org/10.1111/bju.15187openalex-snapshot
Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan
inferred← citeshttps://doi.org/10.1111/cpr.12576openalex-snapshot
δ‐Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells
inferred← citeshttps://doi.org/10.1111/iju.14237openalex-snapshot
Re: Current treatment strategies for advanced prostate cancer
inferred← citeshttps://doi.org/10.1111/iju.14258openalex-snapshot
Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1111/iju.14392openalex-snapshot
Prognosis of metastatic castration‐resistant prostate cancer in the era of the second‐generation androgen receptor‐targeted agents: A retrospective multicenter study
inferred← citeshttps://doi.org/10.1111/iju.15052openalex-snapshot
Efficacy of cabazitaxel in patients with metastatic castration‐resistant prostate cancer: A single‐center study in Japan
inferred← citeshttps://doi.org/10.1111/iju.15498openalex-snapshot
Prognostic outcomes in Japanese patients with metastatic castration‐sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor
inferred← citeshttps://doi.org/10.1111/iju.15550openalex-snapshot
Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy
inferred← citeshttps://doi.org/10.1111/iju.70019openalex-snapshot
Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review
inferred← citeshttps://doi.org/10.1155/2021/1036068openalex-snapshot
Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen
inferred← citeshttps://doi.org/10.1155/2022/2174758openalex-snapshot
SIRT6 Promotes the Progression of Prostate Cancer via Regulating the Wnt/β-Catenin Signaling Pathway
inferred← citeshttps://doi.org/10.1155/2022/5447347openalex-snapshot
Super-Resolution Reconstruction Algorithm-Based MRI Diagnosis of Prostate Cancer and Evaluation of Treatment Effect of Prostate Specific Antigen
inferred← citeshttps://doi.org/10.1155/2022/9516774openalex-snapshot
lncRNA-DANCR Promotes Taxol Resistance of Prostate Cancer Cells through Modulating the miR-33b-5p-LDHA Axis
inferred← citeshttps://doi.org/10.1155/proc/8862153openalex-snapshot
Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A‐Aerobic Glycolysis for Advanced Human Prostate Tumor Growth
inferred← citeshttps://doi.org/10.1159/000505410openalex-snapshot
Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis
inferred← citeshttps://doi.org/10.11606/d.60.2022.tde-14062022-144124openalex-snapshot
Desenvolvimento e caracterização de nanopartículas poliméricas contendo extratos de própolis e avaliação de suas atividades biológicas em células de câncer de próstata
inferred← citeshttps://doi.org/10.1166/jbt.2022.2879openalex-snapshot
Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs)-Derived miR-200c Regulates Wingless-Related Integration Site (Wnt)/β-Catenin Signaling in Prostate Cancer by Targeting Cortactin (CTTN)
inferred← citeshttps://doi.org/10.1172/jci96769openalex-snapshot
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
inferred← citeshttps://doi.org/10.1177/03915603261457521openalex-snapshot
Multiomics empowers predictive drug resistance in advanced prostate cancer
inferred← citeshttps://doi.org/10.1177/03936155231156458openalex-snapshot
Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro
inferred← citeshttps://doi.org/10.1177/10781552241264530openalex-snapshot
Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient
inferred← citeshttps://doi.org/10.1177/1533033821995284openalex-snapshot
Enoxacin Exerts Anti-Tumor Effects Against Prostate Cancer Through Inducing Apoptosis
inferred← citeshttps://doi.org/10.1177/17588359221131532openalex-snapshot
Prostate cancer-associated urinary proteomes differ before and after prostatectomy
inferred← citeshttps://doi.org/10.1186/s11658-023-00508-yopenalex-snapshot
Synthetic CRISPR/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression
inferred← citeshttps://doi.org/10.1186/s12894-022-01113-5openalex-snapshot
Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
inferred← citeshttps://doi.org/10.1186/s12935-020-01508-0openalex-snapshot
Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
inferred← citeshttps://doi.org/10.1186/s12935-023-03042-1openalex-snapshot
Icariin-Curcumol promotes docetaxel sensitivity in prostate cancer through modulation of the PI3K-Akt signaling pathway and the Warburg effect
inferred← citeshttps://doi.org/10.1186/s12943-020-01264-9openalex-snapshot
Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing
inferred← citeshttps://doi.org/10.1186/s12951-024-02438-zopenalex-snapshot
MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC
inferred← citeshttps://doi.org/10.1186/s12957-021-02449-2openalex-snapshot
miRNA-214-5p inhibits prostate cancer cell proliferation by targeting SOX4
inferred← citeshttps://doi.org/10.1186/s40644-023-00523-4openalex-snapshot
Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines
inferred← citeshttps://doi.org/10.12677/wjcr.2021.113013openalex-snapshot
A Bibliometric Analysis of Prostate Cancer Research
inferred← citeshttps://doi.org/10.1272/jnms.jnms.2019_86-609openalex-snapshot
Effect of Orthopedics Promotional Activities on Multidisciplinary Management of Patients with Bone Metastases
inferred← citeshttps://doi.org/10.1371/journal.pone.0208063openalex-snapshot
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
inferred← citeshttps://doi.org/10.14670/hh-18-720openalex-snapshot
RNA-binding protein DND1 participates in migration, invasion, and EMT of prostate cancer cells by degrading CLIC4.
inferred← citeshttps://doi.org/10.1515/oncologie-2023-0233openalex-snapshot
Inhibitory function of CDK12i combined with WEE1i on castration-resistant prostate cancer cells in vitro and in vivo
inferred← citeshttps://doi.org/10.1515/oncologie-2025-0571openalex-snapshot
PSMA theranostics in the evolving landscape of metastatic prostate cancer: challenges and opportunities
inferred← citeshttps://doi.org/10.18535/jmscr/v9i6.42openalex-snapshot
Expression of Androgen Receptor in Invasive Triple Negative Breast Carcinoma
inferred← citeshttps://doi.org/10.18632/aging.204744openalex-snapshot
Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway
inferred← citeshttps://doi.org/10.21037/tau-20-964openalex-snapshot
Narrative review of urinary glycan biomarkers in prostate cancer
inferred← citeshttps://doi.org/10.21037/tau-20-966openalex-snapshot
Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
inferred← citeshttps://doi.org/10.21037/tau-21-1140openalex-snapshot
Telomerase positive CTCs with PSMA high expression associated with prostate cancer metastasis
inferred← citeshttps://doi.org/10.21037/tau-24-49openalex-snapshot
A review of tanshinone compounds in prostate cancer treatment
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1673238/v1openalex-snapshot
Functional genetic variants in circRNA regions associated with susceptibility and prognosis of prostate cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1688738/v1openalex-snapshot
Novel PI3K inhibitor 5d inhibits prostate cancer cell growth in vitro and in vivo
inferred← citeshttps://doi.org/10.21203/rs.3.rs-4113443/v1openalex-snapshot
Feasibility of simultaneous photoselective vaporization of the prostate and MRI/TRUS fusion guided biopsy in patients with suspected prostate cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-5255250/v1openalex-snapshot
Autocrine fibroblast growth factor receptor 1 signaling activates lactate dehydrogenase A-aerobic glycolysis for human prostate cancer DU145 cell growth
inferred← citeshttps://doi.org/10.21203/rs.3.rs-711200/v1openalex-snapshot
The Effect of Upfront Intensive Therapy on Primary Resistance in Metastatic Castration-sensitive Prostate Cancer: A Multicenter Retrospective Study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-90364/v1openalex-snapshot
OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1
inferred← citeshttps://doi.org/10.2147/cmar.s353411openalex-snapshot
Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
inferred← citeshttps://doi.org/10.2147/tcrm.s159824openalex-snapshot
Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
inferred← citeshttps://doi.org/10.21518/2079-701x-2019-19-170-175openalex-snapshot
Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
inferred← citeshttps://doi.org/10.2174/0109298665268943231103114654openalex-snapshot
Novel Circular RNA CircUBAP2 Drives Tumor Progression by Regulating the miR-143/TFAP2B Axis in Prostate Cancer
inferred← citeshttps://doi.org/10.2174/1871520623666230331083744openalex-snapshot
Sinularin Exerts Anti-cancer Effects by Inducing Oxidative Stress-mediated Ferroptosis, Apoptosis, and Autophagy in Prostate Cancer Cells
inferred← citeshttps://doi.org/10.2174/1874467214666210608141102openalex-snapshot
Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer
inferred← citeshttps://doi.org/10.21873/anticanres.13720openalex-snapshot
Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies
inferred← citeshttps://doi.org/10.21873/anticanres.15282openalex-snapshot
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
inferred← citeshttps://doi.org/10.21873/anticanres.15790openalex-snapshot
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease
inferred← citeshttps://doi.org/10.21873/anticanres.16651openalex-snapshot
Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer
inferred← citeshttps://doi.org/10.22141/2663-3272.4.2.2021.238669openalex-snapshot
Clinical significance of anticancer vaccines (literature review)
inferred← citeshttps://doi.org/10.29254/2077-4214-2025-1-176-452-460openalex-snapshot
DYNAMICS OF THE NUCLEAR INDEX AND MITOTIC NUMBER IN HEPATOCYTES UNDER CENTRAL BLOCKADE OF LUTEINIZING HORMONE SYNTHESIS WITH QUERCETIN SUPPLEMENTATION
inferred← citeshttps://doi.org/10.31662/jmaj.2021-0198openalex-snapshot
External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
inferred← citeshttps://doi.org/10.31718/mep.2021.25.5-6.10openalex-snapshot
MORPHOLOGICAL CHANGES AND OXIDATIVE HOMEOSTASIS IN THE LIVER TISSUES DURING LONG CENTRAL DEPRIVATION OF LUTEINIZING HORMONE SYNTHESIS BY TRIPTORELIN
inferred← citeshttps://doi.org/10.3389/fcell.2020.617758openalex-snapshot
OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1
inferred← citeshttps://doi.org/10.3389/fcell.2021.745177openalex-snapshot
Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies
inferred← citeshttps://doi.org/10.3389/fendo.2024.1293953openalex-snapshot
Develop prediction model to help forecast advanced prostate cancer patients’ prognosis after surgery using neural network
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1364329openalex-snapshot
MLXIPL associated with tumor-infiltrating CD8+ T cells is involved in poor prostate cancer prognosis
inferred← citeshttps://doi.org/10.3389/fonc.2018.00635openalex-snapshot
Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
inferred← citeshttps://doi.org/10.3389/fonc.2021.711258openalex-snapshot
Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis
inferred← citeshttps://doi.org/10.3389/fonc.2023.1157384openalex-snapshot
Development, comparison, and validation of four intelligent, practical machine learning models for patients with prostate-specific antigen in the gray zone
inferred← citeshttps://doi.org/10.3389/fonc.2023.1193736openalex-snapshot
RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
inferred← citeshttps://doi.org/10.3389/fonc.2024.1360404openalex-snapshot
Analysis of factors associated with positive surgical margins and the five-year survival rate after prostate cancer resection and predictive modeling
inferred← citeshttps://doi.org/10.3389/fonc.2024.1360956openalex-snapshot
A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapy
inferred← citeshttps://doi.org/10.3389/fonc.2025.1541878openalex-snapshot
5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer
inferred← citeshttps://doi.org/10.3389/fphar.2021.728054openalex-snapshot
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fphar.2022.851589openalex-snapshot
A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment
inferred← citeshttps://doi.org/10.3390/biom12010002openalex-snapshot
Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men
inferred← citeshttps://doi.org/10.3390/cancers12113323openalex-snapshot
Mechanisms of Taxane Resistance
inferred← citeshttps://doi.org/10.3390/cancers13020173openalex-snapshot
Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers13030526openalex-snapshot
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers13071602openalex-snapshot
Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance
inferred← citeshttps://doi.org/10.3390/cancers13081872openalex-snapshot
Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy
inferred← citeshttps://doi.org/10.3390/cancers13143486openalex-snapshot
Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors
inferred← citeshttps://doi.org/10.3390/cancers14122976openalex-snapshot
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10
inferred← citeshttps://doi.org/10.3390/cancers15041192openalex-snapshot
Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cells12050802openalex-snapshot
Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance
inferred← citeshttps://doi.org/10.3390/curroncol31110480openalex-snapshot
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.3390/diagnostics12051113openalex-snapshot
Photodynamic Therapy-Adjunctive Therapy in the Treatment of Prostate Cancer
inferred← citeshttps://doi.org/10.3390/ijms19051359openalex-snapshot
Recent Advances in Prostate Cancer Treatment and Drug Discovery
inferred← citeshttps://doi.org/10.3390/ijms21228724openalex-snapshot
Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
inferred← citeshttps://doi.org/10.3390/ijms22020733openalex-snapshot
Differential DNA Methylation in Prostate Tumors from Puerto Rican Men
showing the first 200 of 237 · page through all 237
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.